Published in Immunotherapy on November 01, 2010
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | NCT00836888
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 | NCT00622401
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget (2015) 0.86
A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells. Clin Vaccine Immunol (2013) 0.80
Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL. Hum Vaccin Immunother (2013) 0.76
LPS-primed Heterotolerant Dendritic Cells suppress Experimental Autoimmune Uveoretintitis by multiple mechanisms. Immunology (2016) 0.75
The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. Med Sci Monit (2016) 0.75
Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. Onco Targets Ther (2016) 0.75
In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes. Int J Nanomedicine (2014) 0.75
Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Oncotarget (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Pathogen recognition and innate immunity. Cell (2006) 44.14
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 6.79
Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol (2006) 6.62
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity (2004) 5.48
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med (2001) 4.78
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol (2002) 3.91
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
TREMs in the immune system and beyond. Nat Rev Immunol (2003) 3.57
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 3.14
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 2.83
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 2.62
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
The first 1000 dendritic cell vaccinees. Cancer Invest (2003) 2.44
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Dendritic cells in vivo: a key target for a new vaccine science. Immunity (2008) 2.31
A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol (2004) 2.30
Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest (2006) 2.29
Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol (2000) 2.29
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 2.09
Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol (2008) 2.05
An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol (2006) 2.04
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Some interfaces of dendritic cell biology. APMIS (2003) 1.79
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med (2008) 1.73
The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol (2006) 1.71
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol (2007) 1.49
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity (2008) 1.40
The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood (2006) 1.37
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol (2009) 1.28
Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol (2008) 1.27
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther (2007) 1.27
Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol (2005) 1.25
The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity (2005) 1.25
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
Regulation of the lifespan in dendritic cell subsets. Mol Immunol (2007) 1.23
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med (2004) 1.22
Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood (2005) 1.22
Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. Eur J Immunol (2008) 1.21
The Dectin-2 family of C-type lectins in immunity and homeostasis. Cytokine (2009) 1.20
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther (2008) 1.19
Dendritic cell trafficking: more than just chemokines. Cytokine Growth Factor Rev (2005) 1.18
Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res (2003) 1.18
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med (2009) 1.18
Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J Immunol (2009) 1.17
IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med (2005) 1.15
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol (2009) 1.12
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med (2007) 1.11
Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol (2006) 1.11
Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Blood (2009) 1.10
Scavenger Receptors SR-AI/II and MARCO limit pulmonary dendritic cell migration and allergic airway inflammation. J Immunol (2007) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res (2006) 1.09
Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother (2002) 1.08
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res (2010) 1.07
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother (2005) 1.06
Complement receptor 3 ligation of dendritic cells suppresses their stimulatory capacity. J Immunol (2007) 1.05
Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood (2003) 1.05
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood (2008) 1.04
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother (2008) 1.02
Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci (2009) 1.01
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res (2004) 1.00
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res (2009) 1.00
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med (2004) 1.72
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther (2012) 1.72
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma (2010) 1.64
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res (2007) 1.58
The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis (2003) 1.57
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood (2004) 1.57
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood (2004) 1.56
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood (2003) 1.54
Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother (2009) 1.52
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood (2008) 1.52
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother (2010) 1.50
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma (2006) 1.46
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol (2005) 1.42
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother (2005) 1.41
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood (2002) 1.40
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther (2009) 1.40
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 1.39
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther (2013) 1.38
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (2010) 1.38
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother (2003) 1.37
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther (2009) 1.36
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant (2005) 1.36
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood (2005) 1.36
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother (2004) 1.35
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther (2009) 1.35
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood (2008) 1.33
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother (2009) 1.32
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther (2011) 1.32
Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma (2005) 1.30
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood (2011) 1.29
Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol (2005) 1.28
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy (2012) 1.27
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother (2008) 1.25
T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther (2010) 1.17
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res (2002) 1.15
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant (2005) 1.13
Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother (2007) 1.08
Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant (2004) 1.07
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol (2003) 1.06
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res (2012) 1.06
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol (2002) 1.06
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 1.04
Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther (2011) 1.03
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther (2004) 1.02
Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother (2007) 1.01
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy (2011) 1.00
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood (2012) 1.00
Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp (2011) 0.98
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther (2011) 0.97
Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet (2011) 0.97
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res (2007) 0.96
Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 0.96
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother (2006) 0.95
Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res (2003) 0.95
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther (2012) 0.94
An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol (2008) 0.94
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother (2013) 0.94
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy (2010) 0.94
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther (2010) 0.92
Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J Immunother (2008) 0.91
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther (2010) 0.91
Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother (2003) 0.91